Literature DB >> 28865056

Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations.

Edithe Selwa1, Eddy Elisée1, Agustin Zavala1, Bogdan I Iorga2.   

Abstract

Our participation to the D3R Grand Challenge 2 involved a protocol in two steps, with an initial analysis of the available structural data from the PDB allowing the selection of the most appropriate combination of docking software and scoring function. Subsequent docking calculations showed that the pose prediction can be carried out with a certain precision, but this is dependent on the specific nature of the ligands. The correct ranking of docking poses is still a problem and cannot be successful in the absence of good pose predictions. Our free energy calculations on two different subsets provided contrasted results, which might have the origin in non-optimal force field parameters associated with the sulfonamide chemical moiety.

Entities:  

Keywords:  Autodock; D3R; Docking; Drug design data resource; FXR; Farnesoid X receptor; Gold; Grand Challenge 2; Scoring function; Vina

Mesh:

Substances:

Year:  2017        PMID: 28865056     DOI: 10.1007/s10822-017-0054-1

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  48 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  Farnesoid X receptor: from structure to potential clinical applications.

Authors:  Roberto Pellicciari; Gabriele Costantino; Stefano Fiorucci
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

3.  Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.

Authors:  Hans G F Richter; G M Benson; K H Bleicher; D Blum; E Chaput; N Clemann; S Feng; C Gardes; U Grether; P Hartman; B Kuhn; R E Martin; J-M Plancher; M G Rudolph; F Schuler; S Taylor
Journal:  Bioorg Med Chem Lett       Date:  2010-12-31       Impact factor: 2.823

Review 4.  Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.

Authors:  Arun J Sanyal
Journal:  Dig Dis       Date:  2015-05-27       Impact factor: 2.404

Review 5.  Farnesoid X receptor modulators (2011 - 2014): a patent review.

Authors:  Valentina Sepe; Eleonora Distrutti; Stefano Fiorucci; Angela Zampella
Journal:  Expert Opin Ther Pat       Date:  2015       Impact factor: 6.674

6.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit.

Authors:  Sander Pronk; Szilárd Páll; Roland Schulz; Per Larsson; Pär Bjelkmar; Rossen Apostolov; Michael R Shirts; Jeremy C Smith; Peter M Kasson; David van der Spoel; Berk Hess; Erik Lindahl
Journal:  Bioinformatics       Date:  2013-02-13       Impact factor: 6.937

Review 7.  Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.

Authors:  Valentina Sepe; Eleonora Distrutti; Vittorio Limongelli; Stefano Fiorucci; Angela Zampella
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

Review 8.  Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities.

Authors:  Christian Gege; Olaf Kinzel; Christoph Steeneck; Andreas Schulz; Claus Kremoser
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 9.  Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.

Authors:  Luciano Adorini; Mark Pruzanski; David Shapiro
Journal:  Drug Discov Today       Date:  2012-05-29       Impact factor: 7.851

Review 10.  The farnesoid X receptor: a novel drug target?

Authors:  Thierry Claudel; Ekkehard Sturm; Folkert Kuipers; Bart Staels
Journal:  Expert Opin Investig Drugs       Date:  2004-09       Impact factor: 6.206

View more
  4 in total

1.  Hybrid receptor structure/ligand-based docking and activity prediction in ICM: development and evaluation in D3R Grand Challenge 3.

Authors:  Polo C-H Lam; Ruben Abagyan; Maxim Totrov
Journal:  J Comput Aided Mol Des       Date:  2018-08-09       Impact factor: 3.686

2.  Blinded evaluation of cathepsin S inhibitors from the D3RGC3 dataset using molecular docking and free energy calculations.

Authors:  Ludovic Chaput; Edithe Selwa; Eddy Elisée; Bogdan I Iorga
Journal:  J Comput Aided Mol Des       Date:  2018-09-11       Impact factor: 3.686

3.  D3R grand challenge 4: blind prediction of protein-ligand poses, affinity rankings, and relative binding free energies.

Authors:  Conor D Parks; Zied Gaieb; Michael Chiu; Huanwang Yang; Chenghua Shao; W Patrick Walters; Johanna M Jansen; Georgia McGaughey; Richard A Lewis; Scott D Bembenek; Michael K Ameriks; Tara Mirzadegan; Stephen K Burley; Rommie E Amaro; Michael K Gilson
Journal:  J Comput Aided Mol Des       Date:  2020-01-23       Impact factor: 3.686

4.  Performance evaluation of molecular docking and free energy calculations protocols using the D3R Grand Challenge 4 dataset.

Authors:  Eddy Elisée; Vytautas Gapsys; Nawel Mele; Ludovic Chaput; Edithe Selwa; Bert L de Groot; Bogdan I Iorga
Journal:  J Comput Aided Mol Des       Date:  2019-11-01       Impact factor: 3.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.